François Gueyffier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
François Gueyffier has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Theodora Bejan-Angoulvant
Medical Pharmacology Department , CHRU de Tours, Tours
7 shared publications - Behrouz Kassai
Hospices Civils de Lyon, EPICIME-CIC 1407 de Lyon, Inserm, Department of Clinical Epidemiology, CHU-Lyon, Bron, France
3 shared publications - Michel Cucherat
Service de pharmacologie clinique, LBBE UMR CNRS 5558, université Lyon 1, 69008 Lyon, France
3 shared publications - Alain Lepape
Department Anaesthesia, General Intensive Care, University hospital, Lyon, France
2 shared publications - Andrea Lorimer
Centro Studi A.N.M.C.O, Firenze, Italy
2 shared publications - Carmen Schade-Brittinger
Coordination Centre for Clinical Trials, Philipps Universität, Marburg, Germany
2 shared publications
Latest Publications
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A39
La diminution de la pression artérielle reflète-t-elle la diminution du risque d’accident cardiovasculaire chez le patient diabétique de type 2 ?
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A39
La diminution de la pression artérielle reflète-t-elle la diminution du risque d’accident cardiovasculaire chez le patient diabétique de type 2 ?
- Open Access
- 10 September 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 1-8
The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with an estimated prevalence of about 1/3000, independent of ethnicity, race, or gender. Attention Deficit Hyperactivity like Disorder (ADHD)-like characteristics are often reported in patients with NF1. We hypothesised that learning disabilities in NF1 children were related to ADHD symptoms. Treatment with methylphenidate (MPD) has improved learning disabilities in ADHD by acting on neurotransmitters. Our objective was to evaluate its efficacy on ADHD-like symptoms in neurofibromatosis type 1 children (7–12 years). This was a randomised, double blind, placebo controlled, and crossover trial comparing 0.5 to 0.8 mg/kg/d of MPD as it is indicated for ADHD to placebo in NF1 children with ADHD-like symptoms. Children aged 7 to 12 years were eligible when their IQ was between 80 and 120. The total follow-up was 9 weeks including 4 weeks for each period and 1 week wash out. Fifty subjects (25 for each period) were required for testing the primary study hypothesis. The main outcome was an improvement in scores on the simplified Conners’ Parent Rating Scale. Thirty-nine patients were included between April 2004 and December 2010. Twenty participants received MPD and 19 placebo during the first period. They all completed the trial. MPD decreased the simplified Conners by 3.9 points (±1.1, p = 0. 0003). This is the first randomised controlled trial showing the short-term benefit of MPD on simplified Conners scores in NF1 children. ClinicalTrials.gov NCT00169611.
- 10 September 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 1-8
Open AccessThe effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with an estimated prevalence of about 1/3000, independent of ethnicity, race, or gender. Attention Deficit Hyperactivity like Disorder (ADHD)-like characteristics are often reported in patients with NF1. We hypothesised that learning disabilities in NF1 children were related to ADHD symptoms. Treatment with methylphenidate (MPD) has improved learning disabilities in ADHD by acting on neurotransmitters. Our objective was to evaluate its efficacy on ADHD-like symptoms in neurofibromatosis type 1 children (7–12 years). This was a randomised, double blind, placebo controlled, and crossover trial comparing 0.5 to 0.8 mg/kg/d of MPD as it is indicated for ADHD to placebo in NF1 children with ADHD-like symptoms. Children aged 7 to 12 years were eligible when their IQ was between 80 and 120. The total follow-up was 9 weeks including 4 weeks for each period and 1 week wash out. Fifty subjects (25 for each period) were required for testing the primary study hypothesis. The main outcome was an improvement in scores on the simplified Conners’ Parent Rating Scale. Thirty-nine patients were included between April 2004 and December 2010. Twenty participants received MPD and 19 placebo during the first period. They all completed the trial. MPD decreased the simplified Conners by 3.9 points (±1.1, p = 0. 0003). This is the first randomised controlled trial showing the short-term benefit of MPD on simplified Conners scores in NF1 children. ClinicalTrials.gov NCT00169611.
- 1 June 2014
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 32 (6) , 1192-1193
Improving risk prediction performance for a better guidelines application
- 1 June 2014
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 32 (6) , 1192-1193
Improving risk prediction performance for a better guidelines application
- Open Access
- 30 August 2013
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 13 (1) , 107
Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review
Background: Open-label, randomized controlled trials (RCTs) are subject to observer bias. If patient management is conducted without blinding, a difference between groups may be explained by other factors than study treatment. One factor may come from taking concomitant treatments with an efficacy on the studied outcomes. In type 2 diabetes, some antihypertensive or lipid-lowering drugs are effective against diabetic complications. We wanted to determine if these concomitant treatments were correctly reported in articles of RCTs on type 2 diabetes and if they might have influenced the outcome. Methods: We performed a systematic review using Medline, Embase, and the Cochrane Library (from January 1950 to July 2010). Open-label RCTs assessing the effectiveness of intensive blood-glucose control in type 2 diabetes were included. We chose five therapeutic classes with proven efficacy against diabetes complications: angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRAs), fibrates, statins, and aspirin. Differences between concomitant treatments were considered statistically significant when p < 0.05. Results: A total of eight open-label RCTs were included, but only three (37.5%) of them published concomitant treatments. In two studies (ACCORD and ADVANCE), a statistically significant difference was observed between the two groups for aspirin (p = 0.02) and ACEIs (p = 0.02). Conclusions: Few concomitant treatments were published in this sample of open-label RCTs. We cannot completely eliminate an observer bias for these studies. This bias probably influenced the results to an extent that has yet to be determined.
- 30 August 2013
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 13 (1) , 107
Open AccessAre concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review
Background: Open-label, randomized controlled trials (RCTs) are subject to observer bias. If patient management is conducted without blinding, a difference between groups may be explained by other factors than study treatment. One factor may come from taking concomitant treatments with an efficacy on the studied outcomes. In type 2 diabetes, some antihypertensive or lipid-lowering drugs are effective against diabetic complications. We wanted to determine if these concomitant treatments were correctly reported in articles of RCTs on type 2 diabetes and if they might have influenced the outcome. Methods: We performed a systematic review using Medline, Embase, and the Cochrane Library (from January 1950 to July 2010). Open-label RCTs assessing the effectiveness of intensive blood-glucose control in type 2 diabetes were included. We chose five therapeutic classes with proven efficacy against diabetes complications: angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRAs), fibrates, statins, and aspirin. Differences between concomitant treatments were considered statistically significant when p < 0.05. Results: A total of eight open-label RCTs were included, but only three (37.5%) of them published concomitant treatments. In two studies (ACCORD and ADVANCE), a statistically significant difference was observed between the two groups for aspirin (p = 0.02) and ACEIs (p = 0.02). Conclusions: Few concomitant treatments were published in this sample of open-label RCTs. We cannot completely eliminate an observer bias for these studies. This bias probably influenced the results to an extent that has yet to be determined.
- Open Access
- 29 August 2013
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 28 (1) , 68-70
Are we using blood pressure-lowering drugs appropriately? Perhaps now is the time for a change
- 29 August 2013
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 28 (1) , 68-70
Open AccessAre we using blood pressure-lowering drugs appropriately? Perhaps now is the time for a change
- 1 May 2012
- Vol. 62 (5) , 687-9
[Training for LCA (Hope study)].
- 1 May 2012
- Vol. 62 (5) , 691-4
[Correction of the proof of LCA [(ECN 2011)].